Hormone therapy for postmenopausal breast cancer survivors: a survey among obstetrician-gynaecologists
Vavilis, D.; Zafrakas, M.; Goulis, D.G.; Pantazis, K.; Agorastos, T.; Bontis, J.N.
European Journal of Gynaecological Oncology 30(1): 82-84
2009
ISSN/ISBN: 0392-2936 PMID: 19317264 Document Number: 634306
To investigate the attitude of Greek obstetrician-gynaecologists towards prescription of hormone therapy to postmenopausal breast cancer survivors. An anonymous questionnaire was sent to members of the Hellenic Society of Obstetrics and Gynaecology with a hypothetical case and a series of relevant questions. Three hundred valid answers were received. Hormone therapy would be prescribed to a breast cancer survivor by only 8%; 80% of these would prefer tibolone. In contrast, 92% would not prescribe hormone therapy; 97% would do so due to the risk of disease recurrence; 70% would not prescribe any alternative therapy, 21% would prescribe CNS-active compounds and 7% SERMs. The vast majority of Greek obstetrician-gynaecologists would not prescribe hormone therapy for menopausal symptoms in breast cancer survivors due to the theoretical risk of disease recurrence. Among those who would not prescribe hormone therapy, 21% would opt to CNS-active compounds.